Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group-Reference-Cited by-同舟云学术

Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

Published:2018-12-12 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Redondo Alba M.¹,Valcárcel David²³,González‐Rodríguez Ana P.⁴,Suárez‐Lledó María⁵,Bello José L.⁶,Canales Miguel⁷,Gayoso Jorge⁸,Colorado Mercedes⁹,Jarque Isidro¹⁰,Campo Raquel¹¹,Arranz Reyes¹²,Terol María J.¹³,Rifón José J.¹⁴,Rodríguez María J.¹⁵,Ramírez María J¹⁶,Castro Nerea¹⁷,Sánchez Andrés¹⁸,López‐Jiménez Javier¹⁹,Montes‐Moreno Santiago²⁰,Briones Javier²¹,López Aurelio²²,Palomera Luis²³,López‐Guillermo Armando⁵,Caballero Dolores¹,Martín Alejandro¹^ORCID,

Affiliation:

1. Department of Haematology Hospital Universitario de Salamanca ‐ IBSAL CIBERONC Salamanca Spain

2. Department of Haematology Hospital Vall d'Hebron University Autònoma of Barcelona (UAB) Barcelona Spain

3. Experimental Haematology Unit Vall d’ Hebron Institute of Oncology (VHIO) Barcelona Spain

4. Department of Haematology Hospital Central de Asturias Oviedo Spain

5. Department of Haematology Hospital Clinic Barcelona Spain

6. Department of Haematology Complejo Hospitalario Universitario de Santiago (CHUS) Santiago de Compostela Spain

7. Department of Haematology Hospital La Paz Madrid Spain

8. Department of Haematology Hospital Gregorio Marañón Madrid Spain

9. Department of Haematology Hospital Marqués de Valdecilla Santander Spain

10. Department of Haematology Hospital Universitario La Fe CIBERONC Valencia Spain

11. Department of Haematology Hospital Son Llítzer Palma de Mallorca Spain

12. Department of Haematology Hospital de La Princesa Madrid Spain

13. Department of Haematology Hospital Clínico de Valencia Valencia Spain

14. Department of Haematology Clínica Universitaria de Navarra Pamplona Spain

15. Department of Haematology Hospital Universitario de Canarias Las Palmas de Gran Canaria Spain

16. Department of Haematology Hospital de Jerez Jerez de la Frontera Spain

17. Department of Haematology Hospital 12 de Octubre Madrid Spain

18. Department of Haematology Hospital Virgen de la Arrixaca Murcia Spain

19. Department of Haematology Hospital Universitario Ramón y Cajal Madrid Spain

20. Department of Pathology Hospital Universitario Marqués de Valdecilla IFIMAV Santander Spain

21. Department of Haematology Hospital Santa Creu i Sant Pau Barcelona Spain

22. Department of Haematology Hospital Arnau de Villanova Valencia Spain

23. Department of Haematology Hospital Clínico de Zaragoza Zaragoza Spain

Funder

Mundipharma

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15713

Reference40 articles.

1. Pretransplant FDG-PET in aggressive non-Hodgkin lymphoma: systematic review and meta-analysis

2. Risk Factors and Outcome of Pulmonary Complications After Autologous Hematopoietic Stem Cell Transplant

3. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era

4. Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

5. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options;Journal of Clinical Medicine;2023-12-22

2. Conditioning regimens: balancing efficacy and toxicity;Leukemia & Lymphoma;2023-06-07

3. Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL);Cancer Research and Treatment;2023-01-15

4. Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge;Transplantation and Cellular Therapy;2023-01

5. Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study;Journal of Clinical Medicine;2022-09-13